Commentary on: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. JAMA. 2006;295:2275-2285
Question: In patients with rheumatoid arthritis treated with infliximab or adalimumab, what is the risk of serious infection or malignancy compared with patients with rheumatoid arthritis who do not receive either anti–tumor necrosis factor (TNF) antibody?
Corona R, Bigby M. What Are the Risks of Serious Infections and Malignancies for Patients Treated With Anti-Tumor Necrosis Factor Antibodies?. Arch Dermatol. 2007;143(3):405-406. doi:10.1001/archderm.143.3.405